Interaction between high power 532nm laser and prostatic tissue: in vivo evaluation for laser prostatectomy

A previous in vitro study demonstrated that 180W was the optimal power to reduce photoselective vaporization of the prostate (PVP) time for larger prostate glands. In this study, we investigated anatomic and histologic outcomes and ablation parameters of 180W laser performed with a new 750-μm side-firing fiber in a survival study of living canines. Eight male canines underwent anterograde PVP with the 180W 532-nm laser. Four each animals were euthanized 3 hours or 8 weeks postoperatively. Prostates were measured and histologically analyzed after hematoxylin and eosin (H&E), triphenyltetrazolium chloride (TTC), or Gomori trichrome (GT) staining. Compared to the previous 120W laser, PVP with the 180W laser bloodlessly created a 76% larger cavity (mean 11.8 vs. 6.7 cm3; p=0.014) and ablated tissue at a 77% higher rate (mean 2.3 vs. 1.3 cm3/min; p=0.03) while H&E- and TTC-staining demonstrated its 33% thicker mean coagulation zone (2.0±0.4 vs. 1.5±0.3 mm). H&E-stained cross-sectional prostatic tissue specimens from the 3-hour (acute) group showed histologic evolution of concentric non-viable coagulation zone, partially viable hyperemic transition zone of repair, and viable non-treated zone. H&E- and GT-stained specimens from the 8-week (chronic) group revealed healed circumferentially epithelialized, non-edematous, prostatic urethral channels with no increase in collagen in the subjacent prostatic tissue vis-á-vis the normal control. Our canine study demonstrates that 180W 532-nm laser PVP with its new fiber has a significantly higher ablation rate with a more hemostatic coagulation zone, but equally favorable tissue interaction and healing, compared with our previous 120W canine study.

[1]  James E. Coad,et al.  Developing clinically successful biomedical devices by understanding the pathophysiology of the target tissue: insights from over 25 years at the microscope , 2007, SPIE BiOS.

[2]  G. Muir,et al.  Photoselective vaporization of the prostate with the potassium‐titanyl‐phosphate laser in men with prostates of >100 mL , 2007, BJU international.

[3]  D M Barrett,et al.  High-power potassium titanyl phosphate laser vaporization prostatectomy. , 1998, Mayo Clinic proceedings.

[4]  Tullio Sulser,et al.  High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. , 2005, The Journal of urology.

[5]  R. Malek GreenLight™ HPS Laser Therapy for BPH: Clinical Outcomes and Surgical Recommendations from the International GreenLight User (IGLU) Group , 2008 .

[6]  M. Hai Photoselective vaporization of prostate: five-year outcomes of entire clinic patient population. , 2009, Urology.

[7]  T. Gasser,et al.  Comparison of potassium‐titanyl‐phosphate laser vaporization of the prostate and transurethral resection of the prostate: update of a prospective non‐randomized two‐centre study , 2008, BJU international.

[8]  Hyun Wook Kang,et al.  Laser vaporization of bovine prostate: a quantitative comparison of potassium-titanyl-phosphate and lithium triborate lasers. , 2008, The Journal of urology.

[9]  R. Malek Photoselective KTP Laser Vaporization of Obstructive BPH (PVP) , 2006 .

[10]  H. Kang,et al.  Greenlight photoselective 120-watt 532-nm lithium triborate laser vaporization prostatectomy in living canines. , 2009, Journal of endourology.

[11]  T. Gasser,et al.  GreenLight laser vaporization of the prostate: single-center experience and long-term results after 500 procedures. , 2008, European urology.

[12]  D. M. Barrett,et al.  High-power potassium-titanyl-phosphate (KTP/532) laser vaporization prostatectomy: 24 hours later. , 1998, Urology.

[13]  D. Bouchier-Hayes Photoselective vaporization of the prostate – towards a new standard , 2007, Prostate Cancer and Prostatic Diseases.

[14]  H. Woo,et al.  Outcome of GreenLight HPS 120-W Laser Therapy in Specific Patient Populations : Those in Retention, on Anticoagulants, and with Large Prostates (≥ 80 ml) , 2008 .

[15]  T. Gasser,et al.  Prospective single‐centre comparison of 120‐W diode‐pumped solid‐state high‐intensity system laser vaporization of the prostate and 200‐W high‐intensive diode‐laser ablation of the prostate for treating benign prostatic hyperplasia , 2009, BJU international.

[16]  D. M. Barrett,et al.  Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. , 2005, The Journal of urology.

[17]  U. Nseyo,et al.  Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. , 2004, The Journal of urology.

[18]  S. Kaplan,et al.  High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates. , 2004, Urology.

[19]  M. Araki,et al.  Short-term outcomes of Greenlight HPS laser photoselective vaporization prostatectomy (PVP) for benign prostatic hyperplasia (BPH). , 2008, Journal of endourology.